Skip to main content
SpringerLink
Log in

Budesonide capsules cause fewer glucocorticoid-related adverse effects than prednisolone during short-term therapy for active Crohn’s disease in adults

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: a model of targeted therapy. Aliment Pharmacol Ther 1997; 11 Suppl. 3: 98–108

    PubMed  CAS  Google Scholar 

  2. McKeage K, Goa K. Budesonide (Entocort EC capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs 2002; 62(15): 2263–82

    Article  PubMed  CAS  Google Scholar 

  3. Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn’s disease in Olmstead County, Minnesota, 1940–1993 incidence, prevalence, and survival. Gastroenterology 1998; 114(6): 1161–8

    Article  PubMed  Google Scholar 

  4. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults: Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2001 Mar; 96: 635–43

    Article  PubMed  CAS  Google Scholar 

  5. British National Formulary. No. 44. London: The Pharmaceutical Press, 2002 Sep

  6. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001 Mar; 96(3): 635–43

    Article  PubMed  CAS  Google Scholar 

  7. Hanauer SB, Greenberger NJ. Updating the approach to Crohn’s disease. Hosp Pract 1999 Aug 15; 34: 77

    Article  CAS  Google Scholar 

  8. Faubion Jr WA, Loftus Jr EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001; 121(2): 255–60

    Article  PubMed  CAS  Google Scholar 

  9. Edsbäcker S, Anderson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse and man: comparative aspects. Drug Metab Dispos 1987; 15(3): 403–11

    PubMed  Google Scholar 

  10. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994 Sep 29; 331(13): 836–41

    Article  PubMed  CAS  Google Scholar 

  11. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Global Budesonide Study Group. Gut 1997 Aug; 41(2): 209–14

    Article  PubMed  CAS  Google Scholar 

  12. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994 Sep 29; 331(13): 842–5

    Article  PubMed  CAS  Google Scholar 

  13. Johansson S-Å, Andersson K-E, Brattsand R, et al. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis 1982; 63 Suppl. 122: 74–82

    Google Scholar 

  14. AstraZeneca. Entocort EC (budesonide) capsules. Prescribing information [online]. Available from URL: http://www.astrazeneca-us.com [Accessed 2002 Feb 2]

  15. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided doses) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002 Jul; 97(7): 1748–54

    Article  PubMed  CAS  Google Scholar 

  16. Thomsen OØ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998 Aug 6; 339(6): 370–4

    Article  PubMed  CAS  Google Scholar 

  17. Kane S, Schoenfeld P, Sandborn W, et al. Effectiveness and safety profile of budesonide in treatment of Crohn’s disease: a systemic review and meta-analysis of randomized controlled trials [abstract]. Am J Gastroenterol 2001 Sep; 96 (Suppl.): S295

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Budesonide capsules cause fewer glucocorticoid-related adverse effects than prednisolone during short-term therapy for active Crohn’s disease in adults. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319060-00001

Keywords

Search

Navigation